Travere Therapeutics (TVTX) Institutional Ownership

During the previous two years, 179 institutional investors and hedge funds held shares of Travere Therapeutics. The most heavily invested institutionals were Vanguard Group Inc. ($117.45M), Deep Track Capital LP ($113.20M), Rock Springs Capital Management LP ($86.64M), Armistice Capital LLC ($66.38M), Renaissance Technologies LLC ($41.97M), Driehaus Capital Management LLC ($38.64M), and State Street Corp ($38.29M).Learn more on TVTX's institutional investors.

Of the 156 institutional investors that purchased Travere Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Assenagon Asset Management S.A. ($2.79M), Driehaus Capital Management LLC ($1.90M), Avidity Partners Management LP ($1.32M), Healthcare of Ontario Pension Plan Trust Fund ($1.28M), Millennium Management LLC ($1.26M), Deep Track Capital LP ($1.22M), and Vanguard Group Inc. ($1.21M).

Institutional investors have bought a total of 33,828,179 shares in the last 24 months. This purchase volume represents approximately $486.17M in transactions.

Of the 73 institutional investors that sold Travere Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Assenagon Asset Management S.A. ($3.12M), Woodline Partners LP ($2.23M), Renaissance Technologies LLC ($1.25M), Great Point Partners LLC ($943K), Jacobs Levy Equity Management Inc. ($892.98K), State Street Corp ($773.98K), and Avidity Partners Management LP ($495.99K).

Institutional investors have sold a total of 14,649,179 shares in the last 24 months. This volume of shares sold represents approximately $204.84M in transactions.